View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

CSL Limited: Update to credit analysis

Our credit view of this issuer reflects a good track record and its plasma-derived therapy industry, constrained by its debt/EBITDA above the 2.75x threshold and its plasma collection costs.

CSL Limited - December 2023 (LTM): Peer Snapshot 

Compares key performance metrics against industry peers.

CSL Limited: Update to credit analysis

Our credit view of this issuer reflects a good track record and its plasma-derived therapy industry, against its debt/EBITDA above the 2.7x threshold and its plasma collection costs.

CSL Limited - June 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

CSL Limited: 2 directors

Two Directors at CSL Limited sold after exercising options/sold 41,000 shares at between 265.549AUD and 265.963AUD. The significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the c...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

CSL Limited: Update after interim results

Our credit view of this issuer reflects a good track record and its plasma-derived therapy industry, against its plasma collection challenges as a result of the pandemic.

CSL Limited - December 2022 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Innoviva Inc: 1 director

A director at Innoviva Inc bought 3,000 shares at 10.868USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

CSL Limited: Fiscal 2022 results support our credit view

Solid results and improving plasma collection will enable CSL to reduce leverage after the Vifor acquisition.

 PRESS RELEASE

Innoviva to Acquire Entasis Therapeutics

BURLINGAME, Calif. & WALTHAM, Mass.--(BUSINESS WIRE)-- Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, and Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) (“Entasis”), an advanced late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the companies have entered into a definitive merger agreement under which Innoviva is to acquire all of the outstanding shares of Entasis not already owned by Innoviva a...

CSL Limited: Update - Offer to acquire Vifor Pharma

Our credit view of this issuer reflects a good track record and its plasma-derived therapy industry, against its plasma collection challenges as a result of the pandemic.

Thanks to a better fundamental star rating, CSL sees an upgrade to Neu...

The independent financial analyst theScreener just awarded an improved star rating to CSL (AU), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 2 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as moderately risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date February 15, 2022, the closi...

CSL Limited: Update - Offer to acquire Vifor Pharma

CSL will continue to reflect an appropriate level of financial risk after the acquisition of Vifor Pharma and is expected to reduce leverage within 18 months of completion.

CSL Limited - June 2021 (LTM): Peer Snapshot

Compares key performance metrics against industry peers

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch